Pharma BD Deal Intelligence

Eli Lilly and Company / Hanmi Pharmaceutical Co., Ltd. (HM71224 program)

2015 · Licensing/Option · $690M · Terminated

Announcement Sentiment

Skeptical

Lilly and Hanmi entered an exclusive worldwide (excluding China, Hong Kong, Korea) license and collaboration for HM71224, an oral BTK inhibitor for autoimmune diseases. Hanmi received $50M upfront with up to $640M in development, regulatory, and sales milestones plus tiered double-digit royalties. Lilly terminated the deal in 2019 after Phase 2 RA trial failed.

Key facts

Announced Mar 19, 2015
Closed Mar 19, 2015
Deal value $690M
Deal type Licensing/Option
Therapeutic area Rheumatoid arthritis, lupus, lupus nephritis, Sjogren's syndrome and other autoimmune diseases
Indications Rheumatoid arthritis, lupus, lupus nephritis, Sjogren's syndrome and other autoimmune diseases
Key assets HM71224 (poseltinib)
Mechanism Oral Bruton's tyrosine kinase (BTK) inhibitor

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals